Navigation Links
FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
Date:2/21/2008

Investigational antiplatelet agent submitted for treatment of patients with

acute coronary syndrome being managed with percutaneous coronary

intervention

TOKYO and INDIANAPOLIS, Feb. 21 /PRNewswire-FirstCall/ -- Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) accepted and designated Priority Review for the New Drug Application for prasugrel, for patients with acute coronary syndrome being managed with percutaneous coronary intervention (PCI). The NDA for prasugrel was submitted to the agency on Dec. 26, 2007.

A priority designation by the FDA sets the PDUFA (Prescription Drug User Fee Act) goal date. The PDUFA goal for priority applications is to have an action provided for 90 percent of applications within six months. FDA can take three different actions - approved, approvable with further discussion, or not approved.

"We are greatly pleased to learn that the FDA has determined the application meets its criteria for such a review, and we look forward to working with the agency as it continues its review process," said Dr. J. Anthony Ware, Lilly vice president for cardiovascular/acute care.

"If approved, prasugrel will provide physicians and acute coronary syndrome patients an alternative medicine that may further help reduce the risk of heart attacks," said John Alexander, M.D., M.P.H., global head of research and development, Daiichi Sankyo Company, Ltd.

About prasugrel

Daiichi Sankyo Company, Limited (TSE: 4568), and Eli Lilly and Company (NYSE:

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
2. Chinese SFDA Grants Immtech Fast Track Status
3. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
4. NTMir Announces Research Grants for Epidemiology and Household Water as Source of Infection
5. FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial
6. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
7. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
8. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
9. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
10. GlaxoSmithKline Accelerates Review of Exelixis XL880
11. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...SALT LAKE CITY, Dec. 4 D...it has signed a sole-source vendor agreement to pr...hmark Physical Therapy with 65 clinics located in ...e named the sole-source supplier to Benchmark Phys...ice president of sales and marketing at Dynatronic...
(Date:12/4/2009)... ,, WASHINGTON, Dec. 4 /PRNewswire-USNews...new report published by the Pharmaceutical Rese...identifies 97 new drugs and vaccines in developmen...e report found that the 97 products in developme...ugs are either in human clinical trials or awaitin...
(Date:12/4/2009)...NNAPOLIS, Md., Dec. 4 Ph...ompany developing medical countermeasures against ...hat the Company is presenting results of a study d...n an inhalation anthrax model in the New Zealand W...uring an oral session at the HHS Public Health Eme...
Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Aton Pharma CEO Mike Wells Named Ernst 26 Young Entrepreneur Of The Year 28R 29 2009 Award Winner 3B 50437 1Aton Pharma CEO Mike Wells Named Ernst 26 Young Entrepreneur Of The Year 28R 29 2009 Award Winner 3B 50437 2Aton Pharma CEO Mike Wells Named Ernst 26 Young Entrepreneur Of The Year 28R 29 2009 Award Winner 3B 50437 3Creighton University St Josephs Hospital and Medical Center Announce New School of Medicine Campus in Phoenix 50434 1Creighton University St Josephs Hospital and Medical Center Announce New School of Medicine Campus in Phoenix 50434 2Statins Might Stave Off Alzheimers 50433 1Statins Might Stave Off Alzheimers 50433 2
...ng a new minimally,invasive procedure to treat ten...gical therapy significantly reduces pain from calc...obility, according to a study presented,today at t...orth America,(RSNA)., "This is a quick, successfu...s," said Luca M. Sconfienza, M.D., from the Depart...
... Ingelheim,Pharmaceuticals, Inc., makers of Viramu... has begun to enroll patients in the NEwArT study ...es. The goal of the NEwArT,study is to compare the...,reverse transcriptase inhibitor (NNRTI) versus at...itonavir. Both agents will be combined with,the fi...
Other Medicine Technology:Minimally Invasive Treatment Reduces Shoulder Pain From Tendonitis 2Minimally Invasive Treatment Reduces Shoulder Pain From Tendonitis 3Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients 2Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients 3
(Date:12/4/2009)...ourism is a phenomenon that was started by people ...rice of dental work in the US, Canada, and other c...care, people have found that Mexican Dental Vacati...on. , (PRWEB) December 4,...ears, Mexican Dental Vacation is seeing their best...
(Date:12/4/2009)...ire/ -- Substantial progress has been made over th...ity to diagnose and treat epilepsy and its complic...has not reached most of the 50 million people arou...illion people in the United States who have the di...D., president of the American Epilepsy Society (AE...
(Date:12/4/2009)...drugs known as statins are among the most prescrib...chers at Fred Hutchinson Cancer Research Center in...ant patients from one of the most serious complica...sus-host disease, or GVHD. The findings are report...od . , In a retrospective study of 567 patients w...
(Date:12/4/2009)... Inventor Showcasing Innovative Health Product in ...mber 4, 2009 -- A valley inventor garnering nation...viduals lose weight, prevent disease, restore heal...owcasing the product at Saturday’s Technolog..., , TrekDesk has been featured on major televisio...
(Date:12/4/2009)...RNewswire-USNewswire/ -- As Congress prepares to v...h Council (FRC) today announced an eight week camp...survey each household on provisions of the Senate ... rationing, higher taxes, and government-run healt... who express opposition to the so-called health ca...
Breaking Medicine News(10 mins):Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 4Health News:Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD 2Health News:Valley Health Invention Making National Splash Showcased at Scottsdale Civic Center Gallery 2Health News:FRC Announces Campaign to Call Every Louisiana Household, Urging Opposition to Health Care Takeover 2
...f Two Additional Strengths Gives ETHEX Full Line o...ability, ST. LOUIS, Oct. 25 KV Pharmaceutical Co...received approval from the U.S.,Food and Drug Admi...roval now allows ETHEX Corporation, KV,s wholly-ow...
...Ore., Oct. 25 - In observance of,World Psoriasis D...ion will,mobilize members and supporters around th...ch and better access to care., World Psoriasis Da..., An estimated 125 million people worldwide suffe...
..., Calif., Oct. 25 Toxic,substances, such as asbes...tes when structures containing the substances burn...ornia Wildfires can harm,the health and property o...tures and the land,surrounding the structures. The...
..., Fla., Oct. 25 Lincare Holdings,Inc. (Nasdaq: L...principal,amount of convertible senior debentures ...d $250 million principal amount of convertible sen... and,sold to qualified institutional buyers pursua...
...TON, Oct. 25 House Republican Whip,Roy Blunt (Mo....rats,attempted once again to use a children,s heal...er-funded care to people who are neither,children ...ith an SCHIP bill that extends quality health care...
... Oct. 25 Fire evacuation from the comfort of,your...he hallway of a,stadium is difficult for anyone. B...g skilled nursing care or assistance with daily li..."We,didn,t get much notice, I had time to grab my ...
Other Medicine News:Health News:KV Pharmaceutical Announces FDA Approval for Morphine ER 100 mg and 200 mg Tablets 2Health News:KV Pharmaceutical Announces FDA Approval for Morphine ER 100 mg and 200 mg Tablets 3Health News:National Psoriasis Foundation Marks World Psoriasis Day With Call to Support Psoriasis Legislation 2Health News:Lincare Holdings Inc. Prices $500 Million Convertible Senior Debentures Offering 2Health News:Lincare Holdings Inc. Prices $500 Million Convertible Senior Debentures Offering 3Health News:St. Paul's Senior Homes & Services Welcomes Some of San Diego's Neediest Displaced Seniors 2Health News:St. Paul's Senior Homes & Services Welcomes Some of San Diego's Neediest Displaced Seniors 3
Kelly Descemet's Membrane Punch
Optec 3500 Vision Tester
Stainless Steel Ruler
Colorado Needle
Medicine Products: